(2005-Lauritano)Rifaximin dose-finding study for the treatment of small intestinal bacterial overgro.pdfVIP

下载本文档

5
0
约1.81万字
约 5页
2017-04-06 发布于江苏
举报
版权申诉

(2005-Lauritano)Rifaximin dose-finding study for the treatment of small intestinal bacterial overgro.pdf

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

(2005-Lauritano)Rifaximin dose-finding study for the treatment of small intestinal bacterial overgro

Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth E. C. LAURITANO, M. GABRIELLI, A. LUPASCU, A. SANTOLIQUIDO, G. NUCERA, E. SCARPELLINI, F. VINCENTI, G. CAMMAROTA, R. FLORE, P. POLA, G. GASBARRINI A. GASBARRINI Internal Medicine Department, Gemelli Hospital, Catholic University of Sacred Heart, Rome, Italy Accepted for publication 12 April 2005 SUMMARY Background: Few controlled studies assessing choice and duration of antibiotic therapy for small intestinal bacterial overgrowth are available. Aim: To assess efficacy, safety and tolerability of different doses of rifaximin, a broad spectrum non-absorbable antibiotic, for intestinal bacterial overgrowth eradica- tion. Methods: We enrolled 90 consecutive patients affected by small intestinal bacterial overgrowth. The presence of small intestinal bacterial overgrowth was based on the occurrence of a rise of H2 values 12 p.p.m. above the basal value after 50 g glucose ingestion. Patients were randomized in three 7-day treatment groups: rifaximin 600 mg/day (group 1); rifaximin 800 mg/day (group 2) and rifaximin 1200 mg/day (group 3). Glucose breath test was reassessed 1 month after the end of therapy. Compliance to the treatment and incidence of side-effects were also evaluated. Results: No drop-outs were observed in the three groups. Glucose breath test normalization rate was significantly higher in group 3 (60%) with respect to group 1 (17%; P 0.001) and group 2 (27%, P 0.01). No sig- nificant differences in patient compliance and incidence of side-effects were found among groups. Conclusions: Higher doses of rifaximin lead to a signifi- cant gain in terms of therapeutic efficacy in small intestinal bacterial overgrowth eradication without increasing the incidence of side-effects. INTRODUCTION Small intestinal bacterial overgrowth (SIBO) is a clinical condition characterized by a malabsorption syndrome because of an increase in micro-organisms to a level exceeding 105 bacteria/